Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Hepatitis C

Study type: Observational

Funder types: Industry

Identifiers

NCT03071133

AI443-144

Details and patient eligibility

About

An observational, postmarketing commitment following the marketing authorization for DCV Trio therapy in Japan

Enrollment: 344 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who are initiating the treatment with DCV Trio therapy under the approved indications, dosage, and administration

Exclusion criteria

• Patients who use the DCV Trio off label